Rapirosiran (sodium)
Rapirosiran sodium is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran sodium can be used for the study of Non-alcoholic steatohepatitis.
Product Specifications
CAS Number
2755197-77-2
Product Name Alternative
ALN-HSD sodium
UNSPSC
12352211
Target
17β-HSD
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
[Rapirosiran(sodium)]
Molecular Formula
C530H676F7N171Na43O323P43S6
Molecular Weight
16307.22 (free acid)
References & Citations
[1]Sanyal AJ, Taubel J, Badri P, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83 (4) :838-848.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880460-100 1x 100 µL
CD44 Standard (156-3C11), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040994-500 1x 500 µL
TNF alpha (J2D10), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040665-500 1x 500 µL
Smooth Muscle Actin (1A4), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 